Noxopharm Anticipates the US FDA's Approval for Evaluating Veyonda in a Clinical Study for COVID-19

Tuba Khan

Shots:

- Noxopharm plans to seek approval to test its Veyonda (idronoxil) on COVID-19 patients in the US, following the research of Hudson Institute about the MOA of idronoxil that holds the potential to block STING signaling, which contributes to lethal self-destruction of major organs in patients with COVID-19
- The company is currently working with the FDA to obtain guidance on the regulatory approval pathway for pursuing the clinical study for COVID-19 patients in the US. Additionally, the company is pursuing the option to test Veyonda in patients with septic shock from infective agents other than the SARS-CoV-2 virus
- Indronoxil inhibits S1P & STING signaling pathways, currently being developed for end-stage PC. The company will evaluate the therapy in patients at risk of developing ARDS and multi-organ failure associated with COVID-19

Click here to read full press release/ article | **Ref:** Noxopharm | **Image:** Noxopharm